Generic medicines are essential to improving access to quality-assured therapy while reducing treatment costs. Although regulatory authorities share the common objectives of assuring quality, safety and efficacy, the requirements, dossier structures, bioequivalence expectations, administrative procedures and post-approval change controls differ among jurisdictions.

Objective: To compare selected regulatory approaches used for generic pharmaceutical products, with emphasis on dossier requirements, common technical formats, bioequivalence and reference-product expectations, approval pathways, timelines, and post-approval change management.

Methods: A comparative regulatory review was undertaken using the supplied project chapters covering ASEAN countries, the European Union, Australia, Canada and the United States, together with the regulatory comparison tables and generic-product assessment information contained in the source material. The comparison focused on regulatory authorities, application pathways, CTD/ACTD structure, quality documentation, bioequivalence, stability, reference-product requirements, manufacturing controls and post-approval variations. Current official regulatory information from FDA, EMA, TGA, Health Canada and ASEAN was also used to contextualize the manuscript.

Results: The review identified a common scientific foundation across the selected jurisdictions, particularly the emphasis on pharmaceutical quality, bioequivalence, appropriate manufacturing controls and lifecycle oversight. However, meaningful differences remain in dossier organization, regional administrative requirements, reference-product selection, local bioequivalence expectations, stability documentation, submission procedures and post-approval change classification. Within ASEAN, the ACTD provides a harmonized structure, but country-specific administrative and technical requirements remain important. The supplied assessment of 25 generic products showed that queries differed by market, with stability/COPP and sample issues prominent in Malaysia, dissolution and translated-label issues prominent in Vietnam, and bioequivalence, method/validation, DMF/starting-material and stability questions prominent in Indonesia and Thailand.

Conclusion: Regulatory convergence has substantially reduced duplication, but harmonization has not eliminated country-specific requirements. A successful multi-country generic development strategy should therefore combine a common core dossier with a country-specific regulatory matrix, early reference-product assessment, robust bioequivalence planning, adequate stability data and proactive lifecycle management.